Loading
A phase 3 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, not yet recruiting.
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT07551479 by Fudan University, with a registry enrolment figure of 612 participants, started 2026-05-01 and due to reach its primary completion in 2032-12-31. Interventions recorded: short-course radiaotherapy; long-course chemoradiaothearpy; Capecitabine; Oxaliplatin; PD-1 inhibitor. Conditions listed: Locally Advanced Rectal Cancer (LARC); MSS (Microsatellite Stable). Primary outcome: 3 year event-free survival rate. Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.